AI Proteins Lands $18.2M in Oversubscribed Seed Round

AI Proteins has built the first platform for designing entirely synthetic proteins from scratch. De novo protein design is finally ready for commercial applications after spending a decade in academia. “With this technology, we will be able to bring next-generation therapeutics to the clinic faster,” said AI Proteins founder, President, and CSO Dr. Chris Bahl.

The $18.2M seed round was co-led by Cobro Ventures and Lightchain Capital, the company announced in a release.

‘De novo design’ allows engineers to design the proteins they want instead of editing existing natural proteins. AI Proteins does this with a novel approach for designing entirely new proteins using an AI-based platform; enabling the development of inexpensive, durable, specific proteins optimized for oral delivery.